Viral Vectors in Gene Therapy

Applications of viral vectors have found an encouraging new beginning in gene therapy in recent years. Significant improvements in vector engineering, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors have been employed for the treatment of various diseases such as metabolic, cardiovascular, muscular, hematologic, ophthalmologic, and infectious diseases and different types of cancer. Recent development in the area of immunotherapy has provided both preventive and therapeutic approaches. Furthermore, gene silencing generating a reversible effect has become an interesting alternative, and is well-suited for delivery by viral vectors. A number of preclinical studies have demonstrated therapeutic and prophylactic efficacy in animal models and furthermore in clinical trials. Several viral vector-based drugs have also been globally approved.

[1]  P. Fisher,et al.  Cancer terminator viruses (CTV): A better solution for viral‐based therapy of cancer , 2018, Journal of cellular physiology.

[2]  K. Odunsi,et al.  Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy , 2018, Cancer Immunology Research.

[3]  K. Lundstrom.  New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy , 2018, Biologics : targets & therapy.

[4]  Wei Xu,et al.  The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. , 2018, Human gene therapy.

[5]  Elizabeth A. Stoll,et al.  Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice , 2017, Human gene therapy methods.

[6]  A. Morton,et al.  Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease. , 2017, Human gene therapy.

[7]  R. MacLaren,et al.  
Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes , 2017, The Yale journal of biology and medicine.

[8]  B. Pfeifer,et al.  Pressing diseases that represent promising targets for gene therapy. , 2017, Discovery medicine.

[9]  P. Monahan,et al.  Gene Therapy for Hemophilia: Progress to Date , 2017, BioDrugs.

[10]  K. Lundstrom.  Latest trends in cancer therapy applying viral vectors , 2017 .

[11]  Wenli Zhang,et al.  Recent Advances in Preclinical Developments Using Adenovirus Hybrid Vectors. , 2017, Human gene therapy.

[12]  S. Yachida,et al.  Strong antitumor efficacy of a pancreatic tumor‐targeting oncolytic adenovirus for neuroendocrine tumors , 2017, Cancer medicine.

[13]  R. Salazar,et al.  Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection , 2017, Journal of Immunotherapy for Cancer.

[14]  Jacob S. Young,et al.  Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma , 2017, Oncotarget.

[15]  J. Foloppe,et al.  Cowpox Virus: A New and Armed Oncolytic Poxvirus , 2017, Molecular therapy oncolytics.

[16]  Chady H Hakim,et al.  Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model. , 2017, Human gene therapy.

[17]  Y. Kodera,et al.  Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials , 2017, Front. Oncol..

[18]  F. Kühnel,et al.  Oncolytic viruses: adenoviruses , 2017, Virus Genes.

[19]  N. Hiraoka,et al.  A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells. , 2017, Anticancer research.

[20]  D. Medina,et al.  Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemicpembrolizumab inadvanced melanoma patients: Interim results of the CAPRA clinical trial , 2017 .

[21]  Zhenyu Zhang,et al.  Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy , 2017, European journal of pharmacology.

[22]  T. He,et al.  Engineering the Rapid Adenovirus Production and Amplification (RAPA) Cell Line to Expedite the Generation of Recombinant Adenoviruses , 2017, Cellular Physiology and Biochemistry.

[23]  Lili Wang,et al.  Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice. , 2017, Human gene therapy.

[24]  Chao Yang,et al.  Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine , 2017, Genes & diseases.

[25]  K. Lundstrom.  Oncolytic Alphaviruses in Cancer Immunotherapy , 2017, Vaccines.

[26]  Martin T. Ferris,et al.  Toward Personalized Gene Therapy: Characterizing the Host Genetic Control of Lentiviral-Vector-Mediated Hepatic Gene Delivery , 2017, Molecular therapy. Methods & clinical development.

[27]  B. Champion,et al.  Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus , 2017, Molecular therapy oncolytics.

[28]  M. Hitt,et al.  Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models , 2017, EMBO molecular medicine.

[29]  J. Johnston,et al.  Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. , 2017, Human gene therapy. Clinical development.

[30]  A. Doherty,et al.  Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis , 2016, Thorax.

[31]  H. Fukuhara,et al.  Oncolytic virus therapy: A new era of cancer treatment at dawn , 2016, Cancer science.

[32]  S. Russell,et al.  Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS. , 2016, Human gene therapy. Clinical development.

[33]  Human Vaccines & Immunotherapeutics: News , 2016 .

[34]  H. Spencer,et al.  State of the art: gene therapy of haemophilia , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  A. Schambach,et al.  Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  T. Mikkelsen,et al.  Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma , 2016, Science Translational Medicine.

[37]  J. Markert,et al.  Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. , 2016, Human gene therapy. Clinical development.

[38]  H. Zeh,et al.  Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  S. Nakagawa,et al.  Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy. , 2016, Biochemical and biophysical research communications.

[40]  K. Lundstrom.  Self-replicating RNA viral vectors in vaccine development and gene therapy , 2016 .

[41]  M. Chattopadhyay,et al.  Viral vector mediated continuous expression of interleukin-10 in DRG alleviates pain in type 1 diabetic animals , 2016, Molecular and Cellular Neuroscience.

[42]  T. Lu,et al.  Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  Shiu-Lok Hu,et al.  Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS , 2016, Molecular therapy. Methods & clinical development.

[44]  J. Li,et al.  Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models , 2016, Gene Therapy.

[45]  D. Duan,et al.  Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy , 2016, Expert opinion on orphan drugs.

[46]  V. Roulstone,et al.  Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer , 2016, Gene Therapy.

[47]  N. Lemoine,et al.  Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. , 2015, Immunotherapy.

[48]  B. Fox,et al.  Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment , 2015, Journal of Immunotherapy for Cancer.

[49]  A. Melcher,et al.  Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients , 2015, Journal of Immunotherapy for Cancer.

[50]  Qingzhong Yu,et al.  Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model , 2015, Technology in cancer research & treatment.

[51]  C. Fraefel,et al.  Novel immunotherapeutic approaches in targeting dendritic cells with virus vectors. , 2015, Discovery medicine.

[52]  Y. Fong,et al.  Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma. , 2015, Surgery.

[53]  G. Hütter,et al.  CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape , 2015, Viruses.

[54]  A. Panet,et al.  Therapeutic potential of oncolytic Newcastle disease virus: a critical review , 2015, Oncolytic virotherapy.

[55]  N. Kasahara,et al.  Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. , 2015, Human gene therapy.

[56]  Liwu Fu,et al.  Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers , 2014, Proceedings of the National Academy of Sciences.

[57]  R. Samulski,et al.  AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. , 2014, Annual review of virology.

[58]  U. Dietrich,et al.  Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. , 2014, Cancer research.

[59]  Michael G. Hanna, Jr.,et al.  Human Vaccines & Immunotherapeutics: News , 2014, Human vaccines & immunotherapeutics.

[60]  G. Ren,et al.  Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy , 2014, Cancer biology & therapy.

[61]  Y. Liu,et al.  Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer , 2014, Virology Journal.

[62]  G. Hortelano,et al.  Sustained expression of coagulation factor IX by modified cord blood‐derived mesenchymal stromal cells , 2014, The journal of gene medicine.

[63]  R. Weichselbaum,et al.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  A. Melcher,et al.  Applications of coxsackievirus A21 in oncology , 2014, Oncolytic virotherapy.

[65]  Rafael J. Yáñez-Muñoz,et al.  Lentiviral vector-mediated RNA silencing in the central nervous system. , 2014, Human gene therapy methods.

[66]  S. Russell,et al.  Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. , 2013, Human gene therapy. Clinical development.

[67]  M. Chattopadhyay.  Targeted delivery of growth factors by HSV-mediated gene transfer for peripheral neuropathy. , 2013, Current gene therapy.

[68]  D. Wallwiener,et al.  Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase. , 2013, Gynecologic oncology.

[69]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[70]  C. von Kalle,et al.  From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. , 2013, Human gene therapy. Clinical development.

[71]  R. Lehmann,et al.  An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis , 2013, Gene Therapy.

[72]  W. Neubert,et al.  A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma. , 2013, Human gene therapy.

[73]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[74]  H. Scher,et al.  A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. , 2013, Vaccine.

[75]  M. Kamata,et al.  Engineering HIV-1-Resistant T-Cells from Short-Hairpin RNA-Expressing Hematopoietic Stem/Progenitor Cells in Humanized BLT Mice , 2012, PloS one.

[76]  V. Grdzelishvili,et al.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. , 2012, The Journal of general virology.

[77]  A. Hinkkanen,et al.  Attenuation of Semliki Forest Virus Neurovirulence by MicroRNA-Mediated Detargeting , 2012, Journal of Virology.

[78]  N. Eberhardt,et al.  Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy , 2012, Cancer Gene Therapy.

[79]  F. Wang,et al.  Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. , 2012, Current gene therapy.

[80]  D. Shafren,et al.  Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride , 2012, Investigational New Drugs.

[81]  D.-S. Kim,et al.  Coxsackievirus B3 used as a gene therapy vector to express functional FGF2 , 2011, Gene Therapy.

[82]  C. Lundberg,et al.  Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease , 2011, The journal of gene medicine.

[83]  S. O’Mara,et al.  Semliki Forest virus‐mediated gene therapy of the RG2 rat glioma , 2010, Neuropathology and applied neurobiology.

[84]  B. S. Manjunath,et al.  Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's Mice , 2010, The Journal of Neuroscience.

[85]  T. Todo,et al.  CLINICAL DEVELOPMENT OF A THIRD-GENERATION ONCOLYTIC HSV-1 (G47Δ) FOR MALIGNANT GLIOMA , 2010 .

[86]  J. Mariadason,et al.  Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors , 2010, Investigational New Drugs.

[87]  S. Kim-Schulze,et al.  Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.

[88]  L. Smeenk,et al.  A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy , 2009, Gene Therapy.

[89]  J. Wahlfors,et al.  Replication competent Semliki Forest virus prolongs survival in experimental lung cancer , 2008, International journal of cancer.

[90]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[91]  D. Kirn,et al.  Gene therapy progress and prospects cancer: oncolytic viruses , 2008, Gene Therapy.

[92]  D. Shafren,et al.  Potent Oncolytic activity of human enteroviruses against human prostate cancer , 2008, The Prostate.

[93]  R. Madan,et al.  PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma , 2007, Expert opinion on biological therapy.

[94]  R. Calne,et al.  Gene therapy for hemophilia A. , 2006, Discovery medicine.

[95]  R. M. Hendry,et al.  Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector , 2006, Springer Seminars in Immunopathology.

[96]  M. K. Sapru,et al.  Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi , 2006, Experimental Neurology.

[97]  H. Kaufman,et al.  Development of the PANVAC™-VF vaccine for pancreatic cancer , 2006, Expert review of vaccines.

[98]  D. Ennist,et al.  CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer , 2006, Clinical Cancer Research.

[99]  K. Lundstrom.  Biology and application of alphaviruses in gene therapy , 2005, Gene Therapy.

[100]  A. Epstein,et al.  HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. , 2005, Current gene therapy.

[101]  A. Thrasher,et al.  Gene therapy for severe combined immunodeficiencies , 2005, Expert opinion on biological therapy.

[102]  Inder M Verma,et al.  Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model , 2005, Nature Neuroscience.

[103]  J. Grieger,et al.  Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps , 2005, Journal of Virology.

[104]  V. Schirrmacher.  Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory , 2005, Cancer Immunology, Immunotherapy.

[105]  T. Rabbitts,et al.  Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. , 2004, The New England journal of medicine.

[106]  P. Hersey,et al.  Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21 , 2004, Clinical Cancer Research.

[107]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[108]  W. Liang,et al.  Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. , 2003, World journal of gastroenterology.

[109]  H. Kaufman,et al.  Poxviruses as vectors for cancer immunotherapy. , 2003, Current opinion in drug discovery & development.

[110]  W. Sterry,et al.  Intradermal injection of Newcastle disease virus‐modified autologous melanoma cell lysate and interleukin‐2 for adjuvant treatment of melanoma patients with resectable stage III disease , 2003, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[111]  D. Baltimore,et al.  Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[112]  H. Zeh,et al.  Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers , 2002, Cancer Gene Therapy.

[113]  M. Mastrangelo,et al.  Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors , 2002, Cancer Gene Therapy.

[114]  J. Marshall,et al.  Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  N. Srinivasakumar.  HIV-1 Vector Systems , 2001, Somatic cell and molecular genetics.

[116]  V. Pathak,et al.  Design of retroviral vectors and helper cells for gene therapy. , 2000, Pharmacological reviews.

[117]  L. Naldini,et al.  Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy , 2000, The journal of gene medicine.

[118]  A. Beaudet,et al.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity , 1998, Nature Genetics.

[119]  S. Gray,et al.  Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome. , 2017, Discovery medicine.

[120]  J. Johnston,et al.  Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. , 2017, Human gene therapy. Clinical development.

[121]  T. Conlon,et al.  SPECIAL FOCUS: PRECLINICAL STUDIES IN LARGE ANIMALS RESEARCH ARTICLES A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System , 2017 .

[122]  A. Schambach,et al.  Retroviral Vectors for Cancer Gene Therapy. , 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[123]  J. Markert,et al.  Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. , 2016, Human gene therapy. Clinical development.

[124]  J. Markert,et al.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[125]  D. Shafren,et al.  Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21 , 2008, Breast Cancer Research and Treatment.

[126]  Wun-Jae Kim,et al.  Cancer gene therapy using adeno-associated virus vectors. , 2008, Frontiers in bioscience : a journal and virtual library.

[127]  T. Wirth,et al.  Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. , 2008, Current molecular pharmacology.

[128]  M. Rots,et al.  State of the Art in Gene Therapy , 2003 .

[129]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.

[130]  L. Weaver,et al.  A multi-mutant herpes simplex virus vector has minimal cytotoxic effects on the distribution of filamentous actin, alpha-actinin 2 and a glutamate receptor in differentiated PC12 cells. , 2000, Journal of neurovirology.

[131]  T. Bakács,et al.  Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). , 1999, Anticancer research.

[132]  C. Bordignon,et al.  Gene Therapy for Severe Combined Immunodeficiencies , 1999 .

[133]  C. Wychowski,et al.  An insight into poliovirus biology. , 1989, Advances in experimental medicine and biology.